Glucose effects on cognition in schizophrenia. 2003

William S Stone, and Larry J Seidman, and Joanne D Wojcik, and Alan I Green
Department of Psychiatry at Massachusetts Mental Health Center (MMHC), Harvard Medical School, 74 Fenwood Road, Boston, MA 02115, USA. william_stone@hms.harvard.edu

Clozapine has been shown to improve verbal declarative memory and other cognitive functions in chronic schizophrenia. This raises the possibility that additional adjunctive manipulations might improve memory further. In this study, we hypothesized that glucose, which improves memory in a variety of conditions, including schizophrenia, would improve memory more than saccharin in a group of patients stabilized on clozapine. Twelve outpatients with schizophrenia who received treatment with clozapine participated in a double-blind, counterbalanced, crossover study. Subjects received beverages containing either glucose or saccharin on one occasion, and then the other beverage about a week later. Fifteen minutes after ingesting the beverage, subjects received a brief battery of neuropsychological tests to assess verbal declarative memory, attention, and executive functions. Blood glucose levels were assessed at baseline, and at 15 and 50 min after beverage ingestion. The main findings were that retention of a list of words was improved in the glucose condition, while performance on a complex test of sustained vigilance declined after glucose ingestion. These findings provide evidence that glucose improves declarative memory in patients with schizophrenia who were treated with clozapine, and underscore the possibility of developing effective protocols to reduce cognitive dysfunctions in the disorder. They also highlight the need to explore the extent to which glucose modulates nonmemory cognitive functions such as attention, and to understand more generally how glucose availability and regulation influence cognition.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009483 Neuropsychological Tests Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury. Aphasia Tests,Cognitive Test,Cognitive Testing,Cognitive Tests,Memory for Designs Test,Neuropsychological Testing,AX-CPT,Behavioral Assessment of Dysexecutive Syndrome,CANTAB,Cambridge Neuropsychological Test Automated Battery,Clock Test,Cognitive Function Scanner,Continuous Performance Task,Controlled Oral Word Association Test,Delis-Kaplan Executive Function System,Developmental Neuropsychological Assessment,Hooper Visual Organization Test,NEPSY,Neuropsychologic Tests,Neuropsychological Test,Paced Auditory Serial Addition Test,Repeatable Battery for the Assessment of Neuropsychological Status,Rey-Osterrieth Complex Figure,Symbol Digit Modalities Test,Test of Everyday Attention,Test, Neuropsychological,Tests, Neuropsychological,Tower of London Test,Neuropsychologic Test,Test, Cognitive,Testing, Cognitive,Testing, Neuropsychological,Tests, Cognitive
D011939 Mental Recall The process whereby a representation of past experience is elicited. Recall, Mental
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005950 Glucose Solution, Hypertonic Solution that is usually 10 percent glucose but may be higher. An isotonic solution of glucose is 5 percent. Hypertonic Glucose Solution,Hypertonic Solution, Glucose,Glucose Solutions, Hypertonic,Hypertonic Solutions, Glucose,Glucose Hypertonic Solution,Glucose Hypertonic Solutions,Hypertonic Glucose Solutions,Solution, Glucose Hypertonic,Solution, Hypertonic Glucose,Solutions, Glucose Hypertonic,Solutions, Hypertonic Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

William S Stone, and Larry J Seidman, and Joanne D Wojcik, and Alan I Green
May 2017, Current opinion in psychiatry,
William S Stone, and Larry J Seidman, and Joanne D Wojcik, and Alan I Green
April 1975, Diseases of the nervous system,
William S Stone, and Larry J Seidman, and Joanne D Wojcik, and Alan I Green
July 1998, Neuropsychology,
William S Stone, and Larry J Seidman, and Joanne D Wojcik, and Alan I Green
January 2021, Frontiers in psychiatry,
William S Stone, and Larry J Seidman, and Joanne D Wojcik, and Alan I Green
April 2005, European archives of psychiatry and clinical neuroscience,
William S Stone, and Larry J Seidman, and Joanne D Wojcik, and Alan I Green
July 2010, Schizophrenia research,
William S Stone, and Larry J Seidman, and Joanne D Wojcik, and Alan I Green
July 2012, Acta psychiatrica Scandinavica,
William S Stone, and Larry J Seidman, and Joanne D Wojcik, and Alan I Green
August 2013, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
William S Stone, and Larry J Seidman, and Joanne D Wojcik, and Alan I Green
August 2013, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
William S Stone, and Larry J Seidman, and Joanne D Wojcik, and Alan I Green
July 2013, Schizophrenia research,
Copied contents to your clipboard!